The United Kingdom and the United States have hammered out a key commercial pact that will maintain no import taxes on UK medicine products entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these key products will be held at zero for a timeframe of the next three years.
This agreement comes after earlier warnings to dramatically increase duties on branded pharmaceutical imports, with potential rates discussed as high as one hundred percent.
"This deal between the United Kingdom reinforces the global environment for cutting-edge drugs and introduces long-overdue fairness to American-British medicine commerce," a release noted.
Commercial Importance
Medicines constitute one of the the United Kingdom's biggest exports to the United States, which is clearly the largest destination for major UK drugmakers.
Statistics indicate that in the year prior to the third quarter, the UK exported medicines valued at £11.1bn to the US. This value accounted for 17.4% of British export trade in that period.
"This guarantee safeguards work, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The pact includes several key commitments from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to increase overall NHS spending on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, refunds topped 20%.
Broader Context
This agreement follows a protracted dispute between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were intensified by arguments that American patients were paying significantly more for the same drugs than people in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
